What's new in transapical aortic valve implantation
Standard
What's new in transapical aortic valve implantation : clinical experience with second generation devices. / Conradi, L; Seiffert, M; Blankenberg, S; Reichenspurner, H; Diemert, P; Treede, H.
in: MINERVA CARDIOANGIOL , Jahrgang 61, Nr. 3, 06.2013, S. 341-349.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - What's new in transapical aortic valve implantation
T2 - clinical experience with second generation devices
AU - Conradi, L
AU - Seiffert, M
AU - Blankenberg, S
AU - Reichenspurner, H
AU - Diemert, P
AU - Treede, H
PY - 2013/6
Y1 - 2013/6
N2 - Within 10 years after transcatheter aortic valve implantation (TAVI) was first accomplished for treatment of calcified aortic stenosis, this new technology has rapidly evolved to become clinical routine. Today it may be considered standard treatment for inoperable patients with superior outcomes compared to best medical therapy. Furthermore, it represents an alternative therapeutic option compared to surgical aortic valve replacement in high-risk patients. According to current international guidelines and expert consensus statements, TAVI should be performed as a joint effort by an interdisciplinary heart team to ensure input from multiple skill sets for optimal patient outcome. Major safety concerns include neurologic complications, acute kidney injury, access site complications, procedure-related conduction disturbances, paravalvular leakage valve durability. At present, only one device for transapical TAVI is in widespread clinical use: the Edwards Sapien transcatheter valve (Edwards Lifesciences, Irvine, CA, USA). Recently, however, a number of second generation devices for transapical TAVI have been developed in order to address some of the limitations of first generation valves. In this paper, current data on second generation devices for transapical TAVI will be reviewed and ongoing trials discussed.
AB - Within 10 years after transcatheter aortic valve implantation (TAVI) was first accomplished for treatment of calcified aortic stenosis, this new technology has rapidly evolved to become clinical routine. Today it may be considered standard treatment for inoperable patients with superior outcomes compared to best medical therapy. Furthermore, it represents an alternative therapeutic option compared to surgical aortic valve replacement in high-risk patients. According to current international guidelines and expert consensus statements, TAVI should be performed as a joint effort by an interdisciplinary heart team to ensure input from multiple skill sets for optimal patient outcome. Major safety concerns include neurologic complications, acute kidney injury, access site complications, procedure-related conduction disturbances, paravalvular leakage valve durability. At present, only one device for transapical TAVI is in widespread clinical use: the Edwards Sapien transcatheter valve (Edwards Lifesciences, Irvine, CA, USA). Recently, however, a number of second generation devices for transapical TAVI have been developed in order to address some of the limitations of first generation valves. In this paper, current data on second generation devices for transapical TAVI will be reviewed and ongoing trials discussed.
KW - Aortic Valve Stenosis/therapy
KW - Cardiac Catheterization/instrumentation
KW - Clinical Trials as Topic
KW - Heart Valve Prosthesis/trends
KW - Heart Valve Prosthesis Implantation/instrumentation
KW - Humans
KW - Practice Guidelines as Topic
KW - Prosthesis Design
KW - Time Factors
KW - Treatment Outcome
M3 - SCORING: Review article
C2 - 23681137
VL - 61
SP - 341
EP - 349
JO - MINERVA CARDIOANGIOL
JF - MINERVA CARDIOANGIOL
SN - 0026-4725
IS - 3
ER -